kidney disease glp-1 news drugs calm inflammation beyond diabetes and weight loss GLP-1 receptor agonists in patients

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications.

Fasting is a practice that has endured centuries

Dual- and triple action approaches which simultaneously target multiple pathways, for example, GLP1R/GIP (tirzepatide), GLP1R/GIP/glucagon (retatrutide) or amylin/GLP1R (CagriSemra) appear more potent and may push weight reduction to the mid-20% range and possibly beyond, while oral options seek to deliver levels of efficacy seen with injectables

BMJ-MAGIC Group publishes recommendations for using SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes.

Enlist the help of a registered dietitian and nutritionist and receive personalized guidance around GLP-1 use and related concerns.